Medical tool
Fragility Fracture Decision Aid
Estimate 10-year risk of major osteoporotic and hip fractures using published hazard ratios. Visualize the impact of bisphosphonate treatment and explore CTFPHC screening recommendations for shared decision-making.
Demographics
Clinical Risk Factors
10-year risk
Out of 100 people like this patient over 10 years:
Treatment Effect
e.g., Alendronate, Risedronate, Zoledronic acid
Contraindicated in esophageal disorders, hypocalcemia, severe renal impairment (eGFR <30–35)
CTFPHC Screening Context
Risk assessment–first screening recommended for females ≥65 years. If pharmacotherapy is considered, request BMD (DXA femoral neck) and re-estimate risk.
Screening not recommended for females 40–64 or males ≥40 (CTFPHC 2023).
Use results to facilitate shared decision-making about potential benefits and harms of preventive pharmacotherapy.
Clinical decision support only. Approximation based on published hazard ratios — not the official FRAX® tool. See CTFPHC 2023 Guideline | Official FRAX®. Not a substitute for clinical judgment.
Methodology, sources, limitations, and privacy
Methodology
The tool estimates 10-year major osteoporotic and hip fracture risk from the selected clinical factors, then applies published relative treatment effects to illustrate absolute risk reduction and number needed to treat.
Sources
Limitations
This educational aid is not the official FRAX calculator and is not a substitute for clinical assessment. Estimates can differ from validated tools and may not apply outside the represented populations, age ranges, or treatment assumptions.
Privacy
Inputs and calculations stay in this browser tab and are not sent to the site server. Do not enter names, record numbers, or other identifying patient information.